![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
GE Healthcare and World Courier, a part of AmerisourceBergen, are combining their expertise in manufacturing and logistics to better patient access to cell and gene therapies.
Together, they aim to create a seamless end-to-end supply chain that will enable the developers of these treatments to meet increasing global demand. This collaboration is designed to support the commercialization of advanced therapies.
By leveraging the manufacturing efficiencies of GE Healthcare’s FlexFactory™, a semi-automated, modular end-to-end manufacturing platform, and World Courier’s robust global logistics platform, drug manufacturers will be able to deliver life-altering therapies that have time- and temperature- critical conditions globally.
Catarina Flyborg, General Manager, Cell and Gene Therapy, GE Healthcare, said: “As GE Healthcare works to advance the development of cell and gene therapies, it is critical that we offer our customers agile solutions that can help them meet global demand. By working with World Courier and leveraging their robust logistics platform and global infrastructure, we are providing a solution that will spur commercialization and access to next generation therapeutics.”
Sam Herbert, President, World Courier, said: “At World Courier, we are committed to moving medicine forward. We’ve developed a proprietary network and global footprint that meets the constantly evolving shipping requirements and complex therapeutics of today. Cell and gene manufacturers deserve a partner that treats patients and their life-changing therapies as well as they would, at every step. By collaborating with GE and their FlexFactory platform, we’re taking our commitment one step further and creating an economic and scalable supply chain that helps ensure the efficient and successful delivery of cell and gene therapies to global patients.”
With more than 900 regenerative medicine companies and more than 1,000 clinical trials underway worldwide in 2018,[1] the industry is growing at an exponential pace. Creating robust supply chains that can efficiently scale up and connect the right therapies to the right patient is key to enabling the commercialization of cell and gene therapies.
About GE Healthcare
GE Healthcare is the $19.8 billion healthcare business of GE . As a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, GE Healthcare enables precision health in diagnostics, therapeutics, and monitoring through intelligent devices, data analytics, applications, and services. With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, the company helps efficiently improve outcomes for patients, healthcare providers, researchers, and life sciences companies around the world. Follow us on Facebook, LinkedIn, Twitter and The Pulse for latest news, or visit our website https://corporate.gehealthcare.com/ for more information.
About World Courier
World Courier provides unparalleled specialty logistics services to drive the commercial success of our partners around the globe. For 50 years, we’ve delivered peace of mind through world-class supply chain programs, transportation services, storage of time- and temperature-sensitive products, and innovative, cutting-edge medicines including cell and gene therapies. Through our daily work – and powered by our nearly 3,000 associates – we are united in our responsibility to create healthier futures. With a presence in 50+ countries, World Courier is driven by a commitment to excellence, and provides customized solutions with global reach to increase access to care; making us the most trusted specialty logistics company in the world. Learn more at worldcourier.com
